TrialPath
Type 2 diabetes · San Jose

Type 2 diabetes clinical trials in San Jose

5 recruiting type 2 diabetes studies within range of San Jose. Click any trial for full eligibility criteria and contact info.

Safer Aging With Diabetes Monitoring

NCT06296485 · Diabetes Mellitus, Type 2, Hypoglycemia
Recruiting

Older adults with type 2 diabetes are at higher risk for severe hypoglycemia and its related complications (including hospitalization and death) when taking insulin. This study proposes to evaluate, in a randomized clinical trial, a strategy of safe insulin prescribing based on an educational program that leverages continuous glucose monitoring to support older adults at high risk for hypoglycemia. If the aims of this project are achieved, this novel care strategy could be widely applied to reduce severe hypoglycemia episodes in older, high-risk adults with type 2 diabetes.

PhaseNA
TypeInterventional
Age75 Years
WhereFremont, California, United States + 5 more
SponsorKaiser Permanente
▾Tap for details
Apply

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

NCT07797335 · Type 2 Diabetes, Cardiovascular Risk
Recruiting

This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medications. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide, (the treatment being tested) or insulin glargine (a comparator) and which treatment participants get is decided by chance.

PhasePhase 3
TypeInterventional
Age45 Years
WhereBirmingham, Alabama, United States + 329 more
SponsorNovo Nordisk A/S
▾Tap for details
Apply

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

NCT07351045 · Obesity or Overweight
Recruiting

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.

PhasePhase 3
TypeInterventional
Age18 Years
WhereAnniston, Alabama, United States + 208 more
SponsorHoffmann-La Roche
▾Tap for details
Apply

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

NCT07351058 · Obesity or Overweight, Type 2 Diabetes Mellitus
Recruiting

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).

PhasePhase 3
TypeInterventional
Age18 Years
WhereGuntersville, Alabama, United States + 221 more
SponsorHoffmann-La Roche
▾Tap for details
Apply

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT07064473 · Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Recruiting

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin. Participants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo. Participants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.

PhasePhase 3
TypeInterventional
Age18 Years
WhereAnniston, Alabama, United States + 1141 more
SponsorBoehringer Ingelheim
▾Tap for details
Apply